SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- Biosite Incorporated
(Nasdaq: BSTE) today announced that it is in discussions with Roche
Diagnostics Corporation regarding a potential settlement of pending
litigation. Biosite and Roche Diagnostics filed joint requests to stay the
litigation in the United States District Courts in the Southern District of
California and the Southern District of Indiana for a period of 120 days.
In the case pending in Indiana, Roche Diagnostics is alleging that Biosite
is infringing two patents, U.S. Patent 5,366,609 and U.S. Patent 4,816,224,
owned by Roche. In the case pending in California, Biosite is alleging that
Roche Diagnostics is infringing three patents, U.S. Patent 6,174,686, U.S.
Patent 5,795,725 and U.S. Patent 6,939,678, owned by Biosite.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in more than 50 international markets. Information on
Biosite can be found at http://www.biosite.com.
Except for the historical information presented herein, matters discussed
in this press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but not
limited to statements that are preceded by, followed by, or that include the
words "will"; "believes"; "should"; "intend"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements are forward-looking statements.
Forward-looking statements in this release include those regarding a potential
settlement of the pending litigation between Biosite and Roche and regarding a
stay of the litigation in the relevant courts. The discussions between Biosite
and Roche may not lead to a settlement of either pending case; any such
settlement, if reached, may not be on favorable terms; and the courts may not
grant the companies' requests for a stay of the litigation. In the event that
the parties are unable to reach a mutually satisfactory settlement or if
either court refuses to grant the requested stay, either party may decide to
continue to prosecute its case. Other risks that should be considered include
those detailed in Biosite's and Roche's respective most recent Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Nadine Padilla, VP, Corporate & Investor
Relations, Biosite Incorporated, +1-858-805-2820,
npadilla@biosite.com
|
